新辅助化疗后保乳手术治疗三阴性乳腺癌的临床疗效分析被引量：12

Analysis of the Clinical Efficacy of Breast-conserving Surgery after Neo-adjuvant Chemotherapy in the Treatment of Triple-negative Breast Cancer

原文传递

导出

摘要目的:探讨不同方案新辅助化疗后行保乳手术治疗三阴性乳腺癌的临床疗效及安全性。方法:收集2006年1月至2015年6月于我院确诊的可手术三阴性乳腺癌患者90例作为研究对象,按照随机数字表法分为观察组及对照组各45例。观察组患者在保乳手术前给予AC-T方案进行新辅助化疗,对照组患者在保乳手术前给予TAC方案进行新辅助化疗。观察并比较两组患者治疗效果、化疗相关不良反应发生情况、术后并发症发生情况以及生活质量的改善情况。结果:观察组总有效率为82.22%,对照组为73.33%;观察组控制率为95.56%,对照组为91.11%,两组总有效率及控制率比较差异无统计学意义(P>0.05);观察组患者中性粒细胞减少、胃肠道不良反应及口腔溃疡发生率均低于对照组(P<0.05),而两组脱发情况比较差异无统计学意义(P>0.05)。两组术后并发症发生率分别为6.67%及11.11%,组间比较差异无统计学意义(P>0.05)。观察组患者术后生活质量改善总有效率为86.67%,对照组总有效率为82.22%,两组相比差异无统计学意义(P>0.05)。结论:在保乳手术前采用AC-T序贯化疗方案进行新辅助化疗治疗三阴性乳腺癌与TAC方案疗效相当,但不良反应明显减少,值得临床推广应用。 Objeetive： To explore the efficacy of different neo-adjuvant methods before breast-eonserving surgery in the treatment of patients with triple-negative breast cancer. Methods： 90 patients with triple-negative breast cancer admitted in our hospital from Jan. 2006 to June 2015 were selected and randomly divided into the observation group and control group with 45 cases in each group. AC-T neo-adjuvant chemotherapy was given to the observation group, and TAC chemotherapy was given to the control group before surgery. Then the efficacy, adverse reactions, complications after surgery and improvement of quality of life in two groups were compared. Results： The total efficacy of observation group and control group were 82.22%, 73.33%. The disease control rate of observation group and control group were 95.56%, 91.11%. There was no significant difference between two groups （P〉0.05）. The incidence rates of neutropenia, gastrointestinal adverse reaction and mouth ulcers of observation roup were obviously lower than those of the control group （P〈0.05）. The complication rate of two groups were 6.67% and 11.11% respectively with no difference between two groups （P〉0.05）. The improvement rate of quality of life was 86.67% and 82.22% in the observation group and control group respectively, which had no statistically significance （P〉0.05）. Conclusion： AC-T neo-adjuvant chemotherapy before breast-conserving surgery had equal efficacy as TAC chemotherapy in the treatment of patients with triple-negative breast cancer, but the adverse reaction of AC-T was obviously less, which was worth clinical application.

作者卜智斌曹强王勇赵渭东宋少伟李晓辉

机构地区渭南市中心医院肿瘤外科延安大学附属医院胸心外科

出处《现代生物医学进展》 CAS 2016年第30期5930-5932,5944,共4页 Progress in Modern Biomedicine

关键词三阴性乳腺癌新辅助化疗 AC-T TAC 保乳手术 Triple-negative breast cancer Neo-adjuvant chemotherapy AC-T TAC Breast-conserving surgery

分类号 R737.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献20

1Dean S J, Rhodes A. Triple negative breast cancer: the role of metabolic pathways[J]. Malays J Pathol, 2014, 36(3): 155-162.
2Marm6 F, Schneeweiss A. Targeted Therapies in Triple-Negative Breast Cancer[J]. Breast Care (Basel), 2015, 10(3): 159-166.
3Liu Y, Xin T, Huang DY, et al. Prognosis in very young women with triple-negative breast cancer: retrospective study of 216 cases [J]. Med Oncol, 2014, 31(12): 222.
4Lowery A J, Kell MR, Glynn RW, et al. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype [J]. Breast Cancer Res Treat, 2012, 133(3): 831-841.
5Garvey EM, Senior DA, Pockaj BA, et al. Rates of residual disease with close but negative margins inbreast cancer surgery [J]. Breast, 2015, 24(4): 413-417.
6Eisenhauer EA, Therasse P, Bogaerts J, et at. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [J]. Eur J Cancer, 2009, 45(2): 228-247.
7Bulut N, Altundag K. Excellent clinical outcome of triple-negative breast cancer in younger and older women [J]. J BUON, 2015, 20(5): 1276-1281.
8Krishnamurthy S, Poornima R, Challa VR, et al. Triple negative breast cancer - our experience and review [J]. Indian J Surg Oncol, 2012, 3 (1):12-16.
9Yaman S, Gumuskaya B, Ozkan C, et al. Lymphatic and capillary invasion pattems in triple negative breast cancer [J]. Am Surg, 2012, 78(11): 1238-1242.
10Han J, Grothuesmann D, Neises M, et al. Quality of life and satisfaction after breast cancer operation [J]. Arch Gynecol Obstet, 2010, 282(1): 75-82.

二级参考文献24

1杨兆禄,尹凤玲,路中,戚丽,邵学叶.乳腺癌术后分阶段放疗的临床观察[J].中华肿瘤防治杂志,2007,14(20):1571-1573. 被引量：2
2Bianco AR, De Matteis A, Manzione L, et al. Sequen- tial epirubicin docetaxel-CMF as adjuvant therapy of early breast cancer: Results of the Taxit 216 multi- center phase 1]] trial [J]. Proc Am Soc Clin Oncol, 2006, 24 . LBA520.
3Jacquemier J, Penauh-Llorca F, Mnif H, et al. Identifi- cation of a basal like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS01 breast cancer trial 33 markers studied on tissue microar- rays(TMA) [J]. Proc Am Soc Clin Oncol, 2006,24 (18S) : Abstract 509.
4Chitapanarnx I, Lorvdhava V, Kammendsupaphon P, et al. Gemcitabine plus cisplatin (GC) : a salvage regi men for advanced break cancer patients who have failed anthracycline and/or taxane therapy[J]. Can To Kagaku Ryoho,2006, 33(6) :761-766.
5Somali I, Alacacioglu A, Tarhan MO, et al. Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline- resistant metastatic breast cancer [J]. Chemotherapy, 2009,55(3) :155-160.
6Nagourney RA, Flare M, Link J, et al. Carboplatin plus gemcitabine repeating doublet therapy in recurrent breast cancer[J]. Clin Breast Cancer, 2008,8 (5) : 432- 435.
7Livi L, Borghesi S, Saieva C, et al. Radiotherapy timing in 4,820 patients with breast cancer:university of florence experience[J]. Int J Radiat Oncol Biol Phys,2009,73(2) :365-369.
8Tsoutsou PG,Belkacemi Y,Gligorov J,et al. Optimal sequential- uence of implied modalities in the adjuvant setting of breast canc- er treatment:an update on issues to consider [J]. The Oneolo- gist,2010,15(11): 1169-1178.
9Alvarado-Mirandal A, Arrieta O, Gamboa-Vignolle C, et al. Con- current chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer[J]. Radiat Oncol, 2009,4: 24.
10Ismaili N, Mellas N, Masbah O, et al. Concurrent chemoradiotherapy in adjuvant treatment of breast cancer[J]. Radiat Oncol, 2009,4(12) 907-916.